HUTCHMED 6-K: SAFFRON phase III enrollment completion noted

Q: What did HCM file?

HUTCHMED filed a Form 6-K furnishing a press release as Exhibit 99.1.

Q: What is highlighted in the 6-K exhibit?

Exhibit 99.1 is a press release on completion of enrollment in the SAFFRON global phase III trial.

Q: Which therapies are in the SAFFRON trial mentioned by HCM?

The trial evaluates a combination of ORPATHYS and TAGRISSO.

Q: Which patients does the SAFFRON trial target?

Certain lung cancer patients with MET overexpression and/or amplification after progression on TAGRISSO.

Q: Which exhibit number contains the press release?

The press release is listed as Exhibit 99.1.

Q: Does HCM file annual reports on Form 20-F or 40-F?

HUTCHMED files annual reports under cover of Form 20-F.

Q: Who signed the submission for HCM?

It was signed by Johnny Cheng, Chief Financial Officer.

Accepted by SEC EDGAR 11/05/2025 - 06:03 AM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

HUTCHMED (CHINA) LIMITED filed a Form 6-K furnishing Exhibit 99.1, a press release about completion of enrollment in the SAFFRON global phase III trial evaluating the combination of ORPATHYS and TAGRISSO for certain lung cancer patients with MET overexpression and/or amplification after progression on TAGRISSO.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did HCM file?

HUTCHMED filed a Form 6-K furnishing a press release as Exhibit 99.1.

What is highlighted in the 6-K exhibit?

Exhibit 99.1 is a press release on completion of enrollment in the SAFFRON global phase III trial.

Which therapies are in the SAFFRON trial mentioned by HCM?

The trial evaluates a combination of ORPATHYS and TAGRISSO.

Which patients does the SAFFRON trial target?

Certain lung cancer patients with MET overexpression and/or amplification after progression on TAGRISSO.

Which exhibit number contains the press release?

The press release is listed as Exhibit 99.1.

Does HCM file annual reports on Form 20-F or 40-F?

HUTCHMED files annual reports under cover of Form 20-F.

Who signed the submission for HCM?

It was signed by Johnny Cheng, Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the Month of November 2025

Commission File Number: 001-37710

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

HUTCHMED (CHINA) LIMITED

Form 6-K

EXHIBIT INDEX


Exhibit No.		Description

Exhibit 99.1		Press release relating to HUTCHMED announces enrollment completed of SAFFRON global phase III trial of ORPATHYS^® and TAGRISSO^® combination for certain lung cancer patients with MET overexpression and/or amplification after progression on TAGRISSO^®

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	HUTCHMED (CHINA) LIMITED


	By:	/s/ Johnny Cheng
	Name:	Johnny Cheng
	Title:	Chief Financial Officer

Date: November 5, 2025

Source: View Original Filing on SEC EDGAR